General provisions related to the pharmaceutical industry including prescription drug affordability and access, intellectual property, privacy, 340B drug discount program policy, and clinical trial diversity issues;
FY2024 Appropriations Process;
Implementation of H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169);
Issues related to the role of pharmacy benefit managers in drug pricing including H.R.6283, DRUG Act.
Issues related to Medicare Part D access and drug pricing negotiation, compulsory licensing policy, and insulin policy.
Issues related to WTO TRIPS.
Intellectual property issues.
Duration: February 1, 2012
to
July 31, 2012
General Issues: Health Issues , Medicare/Medicaid , Trade (Domestic & Foreign) , Copyright/Patent/Trademark , Medical/Disease Research/Clinical Labs
Spending: about $1,090,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2012: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS), Health & Human Services - Dept of (HHS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Steve Tilton HCRPolCoor/SenPolAdvr:ENG/CommBilirakis
J. Michael Hogan Jr. DepCoS, Ben Nelson; LegDir, Peter Deutsch
Gordon Taylor COS/LD/Coun,John;Leg Asst/Press Secy,Hayes
Elena Tompkins Senior Legislative Officer, Labor Dept
John O'Neill PolDir/Coun,SenMinWhip;Couns,SenFinComm
Dean Aguillen Advr, Pelosi; Dir Intgvt Aff, Labor; LA, Sandlin
Sr. Advisor/ Director Member Services/ Floor Asst, Rep. Pelosi; Director Intergovt Affairs/ COS Cong. Affairs/ Special Asst, Labor Dept; LA, Rep. Sandlin
Moses Mercado Dep Chief of Staff, Gephardt; Chief of Staff, Green
Drew Maloney LD/AdAsst,DeLay;Coun,Bryant;LA/Coun,Wicker
Wayne Berman Counselor/Asst Secretary of Commerce for Policy
Karissa Willhite Dep. Chief of Staff, Sen. Menendez; Dep. Exec Director/ Policy Director, House Democratic Caucus; Sr. LA, Rep. Menendez
Dee Buchanan Chief of Staff, House Republican Conference; Chief of Staff/ Dep. Chief of Staff/ Legislative Director, Rep. Jeb Hensarling; Dir, Sen. Phil Gramm
Timothy McGivern Chief of Staff, Senator Sam Brownback
Chris Giblin Chief of Staff, Rep. John Carter; Legislative Director, Rep. Charlie Norwood
Jerome Murray Chief of Staff, Rep. Stacey Plaskett; Legislative Director, Rep. G.K. Butterfield; Associate Director, Democratic Steering and Outreach Committee, Sen. Harry Reid; Legislative Director, Rep. Chaka Fattah; Staff Assistant, Rep. Chaka Fattah
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, OGR lobbied for Pharmaceutical Research and Manufacturers of America (PhRMA) , earning $50,000. The report was filed on April 21.
Original Filing: 301569207.xml
Lobbying Issues
General provisions related to the pharmaceutical industry including prescription drug affordability and access, intellectual property, privacy, 340B drug discount program policy, and clinical trial diversity issues;
FY2024 Appropriations Process;
Implementation of H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169);
Issues related to the role of pharmacy benefit managers in drug pricing including H.R.6283, DRUG Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare Part D access and drug pricing negotiation, compulsory licensing policy, and insulin policy.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to WTO TRIPS.
Intellectual property issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2023
In Q4, OGR (formerly known as Ogilvy Government Relations) lobbied for Pharmaceutical Research and Manufacturers of America (PhRMA) , earning $50,000. The report was filed on Jan. 21.
Original Filing: 301534622.xml
Lobbying Issues
General provisions related to the pharmaceutical industry including prescription drug affordability and access, intellectual property, privacy, 340B drug discount program policy, and clinical trial diversity issues;
FY2024 Appropriations Process;
Implementation of H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169);
Issues related to the role of pharmacy benefit managers in drug pricing including H.R.6283, DRUG Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare Part D access and drug pricing negotiation, compulsory licensing policy, and insulin policy.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to WTO TRIPS.
Intellectual property issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2023
In Q3, Ogilvy Government Relations lobbied for Pharmaceutical Research and Manufacturers of America (PhRMA) , earning $50,000. The report was filed on Oct. 19, 2023.
Original Filing: 301509145.xml
Lobbying Issues
General provisions related to the pharmaceutical industry including prescription drug affordability and access, intellectual property, privacy, 340B drug discount program policy, and clinical trial diversity issues;
FY2024 Appropriations Process;
Implementation of H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169);
Monitoring public health emergency designation;
Issues related to the role of pharmacy benefit managers in drug pricing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare Part D access and drug pricing negotiation, compulsory licensing policy, and insulin policy.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to WTO TRIPS.
Intellectual property issues.
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2023
In Q2, Ogilvy Government Relations lobbied for Pharmaceutical Research and Manufacturers of America (PhRMA) , earning $50,000. The report was filed on July 20, 2023.
Original Filing: 301487235.xml
Lobbying Issues
General provisions related to the pharmaceutical industry including prescription drug affordability and access, intellectual property, privacy, 340B drug discount program policy, and clinical trial diversity issues.
Implementation of H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169).
Monitoring public health emergency designation.
Issues related to the role of pharmacy benefit managers in drug pricing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare Part D access and drug pricing negotiation, compulsory licensing policy, and insulin policy.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to WTO TRIPS.
Intellectual property issues.
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2023
In Q1, Ogilvy Government Relations lobbied for Pharmaceutical Research and Manufacturers of America (PhRMA) , earning $50,000. The report was filed on April 19, 2023.
Original Filing: 301459088.xml
Lobbying Issues
General provisions related to the pharmaceutical industry including prescription drug affordability and access, intellectual property, privacy, 340B drug discount program policy, and clinical trial diversity issues.
Implementation of H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169).
Monitoring public health emergency designation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare Part D access and drug pricing negotiation, compulsory licensing policy, and insulin policy.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to WTO TRIPS.
Intellectual property issues.
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2022
In Q4, Ogilvy Government Relations lobbied for Pharmaceutical Research and Manufacturers of America (PhRMA) , earning $50,000. The report was filed on Jan. 19, 2023.
Original Filing: 301436116.xml
Lobbying Issues
General prescription drug affordability and access.
Intellectual Property issues.
PDUFA Reauthorization; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.2617, Consolidated Appropriations Act, 2023.
Provisions related to the pharmaceutical industry; FY2023 Appropriations Process; monitoring COVID Supplemental Funding.
Privacy issues; H.R.8152, American Data Privacy and Protection Act.
340B drug discount program policy issues.
Clinical trial diversity issues.
Implementation of H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Part D access and drug pricing negotiation.
Compulsory licensing policy issues.
Insulin policy issues; Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act (draft legislation); S.3700, Affordable Insulin Now Act; implementation of H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to WTO TRIPS Waiver.
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2022
In Q3, Ogilvy Government Relations lobbied for Pharmaceutical Research and Manufacturers of America (PhRMA) , earning $50,000. The report was filed on Oct. 19, 2022.
Original Filing: 301410468.xml
Lobbying Issues
General prescription drug affordability and access.
Intellectual Property issues.
PDUFA Reauthorization; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180).
Provisions related to the pharmaceutical industry; FY2023 Appropriations Process; monitoring COVID Supplemental Funding.
Privacy issues; H.R.8152, American Data Privacy and Protection Act.
340B drug discount program policy issues.
Clinical trial diversity issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Part D access and drug pricing negotiation.
Compulsory licensing policy issues.
Insulin policy issues; Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act (draft legislation); S.3700, Affordable Insulin Now Act; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to WTO TRIPS Waiver.
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2022
In Q2, Ogilvy Government Relations lobbied for Pharmaceutical Research and Manufacturers of America (PhRMA) , earning $50,000. The report was filed on July 19, 2022.
Original Filing: 301385463.xml
Lobbying Issues
General prescription drug affordability and access.
Intellectual Property issues.
PDUFA Reauthorization; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022.
Provisions related to the pharmaceutical industry; FY2023 Appropriations Process; monitoring COVID Supplemental Funding.
Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act (draft legislation).
Privacy issues; H.R.8152, American Data Privacy and Protection Act.
340B drug discount program policy issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Part D access and drug pricing negotiation; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; FY2022 Budget Reconciliation (H.R.5376).
Compulsory licensing policy issues.
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, Ogilvy Government Relations lobbied for Pharmaceutical Research and Manufacturers of America (PhRMA) , earning $50,000. The report was filed on April 20, 2022.
Original Filing: 301367346.xml
Lobbying Issues
General prescription drug affordability and access.
Intellectual Property issues.
PDUFA Reauthorization.
Provisions related to the pharmaceutical industry; FY2022 Consolidated Appropriations Act (H.R.2471, P.L.117-103); H.R.7007, COVID Supplemental Appropriations Act, 2022.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Part D access and drug pricing negotiation; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; FY2022 Budget Reconciliation (H.R.5376).
Compulsory licensing policy issues.
Agencies Lobbied
U.S. Senate
4th Quarter, 2021
In Q4, Ogilvy Government Relations lobbied for Pharmaceutical Research and Manufacturers of America (PhRMA) , earning $50,000. The report was filed on Jan. 19, 2022.
Original Filing: 301326536.xml
Lobbying Issues
General prescription drug affordability and access.
Intellectual Property issues.
Provisions related to the pharmaceutical industry; FY2022 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.4356/S.2599); FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.4502/S.3062).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Part D access and drug pricing negotiation; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; FY2022 Budget Resolution (S.Con.Res.14)/Budget Reconciliation (H.R.5376).
Compulsory licensing policy issues.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, Ogilvy Government Relations lobbied for Pharmaceutical Research and Manufacturers of America (PhRMA) , earning $50,000. The report was filed on Oct. 19, 2021.
Original Filing: 301303927.xml
Lobbying Issues
General prescription drug affordability and access.
Intellectual Property issues.
Provisions related to the pharmaceutical industry; FY2022 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.4356/S.2599); FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.4502).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Part D access and drug pricing negotiation; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; FY2022 Budget Resolution (S.Con.Res.14)/Budget Reconciliation (H.R.5376).
Compulsory licensing policy issues.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, Ogilvy Government Relations lobbied for Pharmaceutical Research and Manufacturers of America (PhRMA) , earning $50,000. The report was filed on July 19, 2021.
Original Filing: 301280485.xml
Lobbying Issues
General prescription drug affordability and access.
Intellectual Property issues.
Advise client on nature and status of various COVID-19 legislative proposals.
Provisions related to the pharmaceutical industry; FY2022 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Part D access and drug pricing negotiation; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act.
Compulsory licensing policy issues.
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, Ogilvy Government Relations lobbied for Pharmaceutical Research and Manufacturers of America (PhRMA) , earning $50,000. The report was filed on April 18, 2021.
Original Filing: 301255639.xml
Lobbying Issues
General prescription drug affordability and access.
Intellectual Property issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Part D access and drug pricing negotiation.
Compulsory licensing policy issues.
Advise client on nature and status of various COVID-19 legislative proposals; Medicaid rebates; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2).
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, Ogilvy Government Relations lobbied for Pharmaceutical Research and Manufacturers of America (PhRMA) , earning $50,000. The report was filed on Jan. 20, 2021.
Original Filing: 301237460.xml
Lobbying Issues
General prescription drug affordability and access.
FDA provisions related to prescription drugs; FY2021 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.7610).
Advise client on and status of various COVID-19 legislative proposals.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions related to Part D access and drug pricing negotiation.
Compulsory licensing policy issues.
H.R.1046, Medicare Negotiation and Competitive Licensing Act of 2019.
H.R.3, Lower Drug Costs Now Act of 2019.
S.2543, Prescription Drug Pricing Reduction Act of 2019.
H.R.1425, Patient Protection and Affordable Care Enhancement Act.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, Ogilvy Government Relations lobbied for Pharmaceutical Research and Manufacturers of America (PhRMA) , earning $50,000. The report was filed on Oct. 17, 2020.
Original Filing: 301212617.xml
Lobbying Issues
General prescription drug affordability and access.
FDA provisions related to prescription drugs; FY2021 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.7610).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions related to Part D access and drug pricing negotiation.
Compulsory licensing policy issues.
H.R.1046, Medicare Negotiation and Competitive Licensing Act of 2019.
H.R.3, Lower Drug Costs Now Act of 2019.
S.2543, Prescription Drug Pricing Reduction Act of 2019.
H.R.1425, Patient Protection and Affordable Care Enhancement Act.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, Ogilvy Government Relations lobbied for Pharmaceutical Research and Manufacturers of America (PhRMA) , earning $50,000. The report was filed on July 18, 2020.
Original Filing: 301193231.xml
Lobbying Issues
General prescription drug affordability and access.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions related to Part D access and drug pricing negotiation.
Compulsory licensing policy issues.
H.R.1046, Medicare Negotiation and Competitive Licensing Act of 2019.
H.R.3, Lower Drug Costs Now Act of 2019.
S.2543, Prescription Drug Pricing Reduction Act of 2019.
H.R.1425, Patient Protection and Affordable Care Enhancement Act.
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, Ogilvy Government Relations lobbied for Pharmaceutical Research and Manufacturers of America (PhRMA) , earning $50,000. The report was filed on April 20, 2020.
Original Filing: 301175534.xml
Lobbying Issues
General prescription drug affordability and access.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions related to Part D access and drug pricing negotiation.
Compulsory licensing policy issues.
H.R.1046, Medicare Negotiation and Competitive Licensing Act of 2019.
H.R.3, Lower Drug Costs Now Act of 2019.
S.2543, Prescription Drug Pricing Reduction Act of 2019.
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, Ogilvy Government Relations lobbied for Pharmaceutical Research and Manufacturers of America (PhRMA) , earning $50,000. The report was filed on Jan. 18, 2020.
Original Filing: 301121156.xml
Lobbying Issues
General prescription drug affordability and access.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions related to Part D access and drug pricing negotiation.
Compulsory licensing policy issues.
H.R.1046, Medicare Negotiation and Competitive Licensing Act of 2019.
H.R.3, Lower Drug Costs Now Act of 2019.
S.2543, Prescription Drug Pricing Reduction Act of 2019.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, Ogilvy Government Relations lobbied for Pharmaceutical Research and Manufacturers of America (PhRMA) , earning $50,000. The report was filed on Oct. 19, 2019.
Original Filing: 301072039.xml
Lobbying Issues
General prescription drug affordability and access.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions related to Part D access and drug pricing negotiation.
Compulsory licensing policy issues.
Proposed HHS Rule on Rebates.
H.R.1046, Medicare Negotiation and Competitive Licensing Act of 2019.
H.R.3, Lower Drug Costs Now Act of 2019.
S.2543, Prescription Drug Pricing Reduction Act of 2019.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, Ogilvy Government Relations lobbied for Pharmaceutical Research and Manufacturers of America (PhRMA) , earning $50,000. The report was filed on July 21, 2019.
Original Filing: 301053773.xml
Lobbying Issues
General prescription drug affordability and access.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions related to Part D access and drug pricing negotiation.
Compulsory licensing policy issues.
H.R.1046, Medicare Negotiation and Competitive Licensing Act of 2019.
Proposed HHS Rule on Rebates.
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, Ogilvy Government Relations lobbied for Pharmaceutical Research and Manufacturers of America (PhRMA) , earning $30,000. The report was filed on April 21, 2019.
Original Filing: 301032802.xml
Lobbying Issues
General prescription drug affordability and access.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions related to Part D access and drug pricing negotiation;
Compulsory licensing policy issues;
H.R.1046, Medicare Negotiation and Competitive Licensing Act of 2019.
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
Ogilvy Government Relations filed a lobbying registration on March 15, 2019 to represent Pharmaceutical Research and Manufacturers of America (PhRMA), effective Feb. 1, 2019.
Original Filing: 301021568.xml
Issue(s) they said they’d lobby about: General prescription drug affordability and access. Provisions related to Part D access and drug pricing negotiation; Compulsory licensing policy issues; H.R.1046, Medicare Negotiation and Competitive Licensing Act of 2019. .
3rd Quarter, 2012
Ogilvy Government Relations terminated an engagement in which they represented Pharmaceutical Research and Manufacturers of America (PhRMA) on Oct. 18, 2012.
Original Filing: 300511958.xml
Lobbying Issues
Issues related to the implementation of the Patient Protection and Affordable Care Act;
Prescription Drug User Fee Act (PDUFA) reauthorization and other related Food and Drug Administration issues;
general issues related to the pharmaceutical industry.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.1249, America Invents Act, issues related to patent reform.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to Medicare and Medicaid.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S.3187/H.R.5651, Food and Drug Administration Safety and Innovation Act (Public Law No: 112-144);
Medical Device User Fee Act and related issues.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
2nd Quarter, 2012
Ogilvy Government Relations amended a lobbying report for representation of Pharmaceutical Research and Manufacturers of America (PhRMA) in Q22012 on July 20, 2012.
Original Filing: 300495800.xml
Lobbying Issues
Issues related to the implementation of the Patient Protection and Affordable Care Act;
Prescription Drug User Fee Act (PDUFA) reauthorization and other related Food and Drug Administration issues;
general issues related to the pharmaceutical industry.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.1249, America Invents Act, issues related to patent reform.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to Medicare and Medicaid.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2012
In Q2, Ogilvy Government Relations lobbied for Pharmaceutical Research and Manufacturers of America (PhRMA) , earning $30,000. The report was filed on June 18, 2012.
Original Filing: 300479653.xml
Lobbying Issues
Issues related to the implementation of the Patient Protection and Affordable Care Act;
Prescription Drug User Fee Act (PDUFA) reauthorization and other related Food and Drug Administration issues;
general issues related to the pharmaceutical industry.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.1249, America Invents Act, issues related to patent reform.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to Medicare and Medicaid.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2012
In Q1, Ogilvy Government Relations lobbied for Pharmaceutical Research and Manufacturers of America (PhRMA) , earning $20,000. The report was filed on April 18, 2012.
Original Filing: 300462955.xml
Lobbying Issues
Issues related to the implementation of the Patient Protection and Affordable Care Act;
Prescription Drug User Fee Act (PDUFA) reauthorization and other related Food and Drug Administration issues;
general issues related to the pharmaceutical industry.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.1249, America Invents Act, issues related to patent reform.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to Medicare and Medicaid.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2012
Ogilvy Government Relations filed a lobbying registration on Feb. 5, 2012 to represent Pharmaceutical Research and Manufacturers of America (PhRMA), effective Feb. 1, 2012.
Original Filing: 300455181.xml
Issue(s) they said they’d lobby about: Issues related to the implementation of the Patient Protection and Affordable Care Act, Prescription Drug User Fee Act reauthorization, health care, copyright/patent/trademark and Medicare/Medicaid. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...